Core Viewpoint - The company International Medicine (000516) is facing challenges related to its stock performance and ongoing capital increase plans, amid concerns over major shareholder actions and industry policy changes [1][2][3] Group 1: Stock Performance - As of February 5, 2026, International Medicine's stock closed at 4.95 yuan, down 0.4%, with a turnover rate of 1.41%, trading volume of 311,800 shares, and a transaction value of 155 million yuan [1] - On the same day, there was a net outflow of 14.1651 million yuan from major funds, indicating a short-term reduction in holdings by institutional investors [3] Group 2: Capital Increase and Shareholder Concerns - The company is currently in the process of a non-public offering, but the specific issuance targets have not yet been determined, leading to investor concerns about potential shareholder dilution and stock price impacts [2] - Major shareholder Century Xinyuan has pledged 82.07% of its shares as of mid-January 2026, raising questions about control and financial stability, although the company asserts that the risk is manageable [2] Group 3: Operational Strategies - In response to ongoing healthcare policy reforms, the company is focusing on enhancing operational efficiency and cost control, particularly in specialized medical fields such as neurology, cardiology, and oncology [2][3] - The company is also exploring differentiated business strategies in areas like aesthetic medicine, rehabilitation, and elder care to build competitive advantages and improve service value [2]

证券之星消息，截至2026年2月5日收盘，国际医学(000516)报收于4.95元，下跌0.4%，换手率1.41%， 成交量31.18万手，成交额1.55亿元。 近5日资金流向一览见下表： 该股最近90天内共有2家机构给出评级，增持评级2家；过去90天内机构目标均价为5.5。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3. ...

证券日报网讯 2月5日，国际医学（000516）在互动平台回答投资者提问时表示，面对当前行业政策， 特别是医保支付改革的深化，公司与旗下医疗机构坚持规范运营，不断强化成本管控和效率提升，已在 优势专科建设、差异化业务布局上采取了一系列措施，实现了运营效率的持续优化、经营业绩的改善提 升。 ...

证券日报网讯 2月5日，国际医学（000516）在互动平台回答投资者提问时表示，公司控股股东及一致 行动人资信状况良好，具备较强的资金偿还能力，质押风险可控。 ...

证券日报网讯 2月5日，国际医学在互动平台回答投资者提问时表示，关于公司2026年度的经营与财务 情况，请留意公司后续披露的定期报告。 （文章来源：证券日报） ...

证券日报网讯 2月5日，国际医学在互动平台回答投资者提问时表示，"国际医学"的名称凝聚了公司"汇 聚人类生命科学智慧，同步国际先进诊疗水平"的愿景。 （文章来源：证券日报） ...

Core Viewpoint - The company is adapting to industry policy adjustments, particularly the ongoing deepening of medical insurance payment reforms, by strengthening its specialized departments and exploring new service areas to build a competitive advantage and enhance service value [1] Group 1: Specialized Departments - The company is focusing on enhancing its strengths in specialized departments such as neurology, cardiovascular, digestive, thoracic, oncology, hematology, and orthopedics to create a solid "moat" [1] - Continuous improvement in operational efficiency and business performance is being achieved through clinical pathway management and promotion of day surgery [1] Group 2: New Service Areas - The company is actively exploring and laying out services in aesthetic medicine, rehabilitation, maternal and child health, health management, traditional Chinese medicine, assisted reproduction, mental health, special needs services, elderly care, and proton therapy [1] - A differentiated strategy is being employed to construct competitive advantages in these new service areas [1] Group 3: Operational Efficiency - The company and its subsidiaries are committed to standardized operations, which include a series of measures aimed at cost control and efficiency enhancement [1] - The focus on operational efficiency is leading to continuous optimization and improvement in business performance [1]

格隆汇2月5日丨国际医学(000516.SZ)在互动平台表示，公司控股股东及一致行动人质押的股票不涉及 转融通业务。 ...

公司公告汇总 西安国际医学投资股份有限公司预计2025年度归属于上市公司股东的净利润亏损29,500万元至31,500万 元，较上年同期亏损25,412.85万元同比扩大。扣除非经常性损益后的净利润预计亏损32,000万元至 35,000万元。营业收入预计为406,000万元至408,000万元，较上年同期481,546.68万元下降。公司称受市 场波动、DRG支付政策改革等因素影响，营业收入同比下降，虽实施降本增效措施使第四季度亏损收 窄，但收入规模尚未覆盖运营成本和期间费用。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：国际医学预计2025年归属净利润亏损2.95亿元至3.15亿元。 公司公告汇总：国际医学2025年度营收预计为40.6亿元至40.8亿元，同比下滑。 截至2026年1月30日收盘，国际医学（000516）报收于4.89元，较上周的5.21元下跌6.14%。本周，国际 医学1月26日盘中最高价报5.26元。1月30日盘中最低价报4.84元。国际医学当前最新总市值10 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].